Zydus Cadila gets tentative nod from USFDA for Fingolimod Capsules

It also said that earlier, in October 2020, the group was granted approval to market Fingolimod capsules in the strength of 0.5mg.

39
USFDA
Picture: Pixabay

Last Updated on June 26, 2021 by The Health Master

Zydus Cadila has received tentative approval from the United States US (USFDA) to market Fingolimod capsules in the strength of 0.25 mg (US RLD: Gilenya capsules), the company informed in a statement.

It also said that earlier, in October 2020, the group was granted approval to market Fingolimod capsules in the strength of 0.5mg. It is an immunomodulating drug. It is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS).

“The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad,” added the statement.

The group now has 319 approvals and has so far filed over 400 Abbreviated New Drug Applications (ANDAs) since the commencement of the filing process in FY 2003-04, it said.

Alkem gets two observations from USFDA for USA plant

Lupin gets USFDA nod for treatment of Kidney patient

Aleor gets USFDA nod for Testosterone Topical Solution

Avenue Therapeutics gets complete response letter from USFDA for IV Tramadol

Natco gets USFDA nod for Carfilzomib Injection

Lupin gets warning letter from USFDA for Somerset facility

IPC to sensitize stakeholders on manufacturing of Quality Drugs

J Mitra and Company launches C-19 Microlisa Elisa Test kit

Mankind launches drug to treat Diabetes, Heart failure

Dr. Reddy’s Labs launches Icosapent Ethyl Capsules

Cadila Pharma launches Posaconazole to treat fungal diseases

European Commission approves Empagliflozin to treat heart failure

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner